TENAX THERAPEUTICS, INC. Amortization of Leased Asset
TENAX THERAPEUTICS, INC. (TENX) reported Amortization of Leased Asset of $53.03 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfLeasedAsset · last filed 2022-08-11
- TENAX THERAPEUTICS, INC. amortization of leased asset for the quarter ending 2022-06-30 was $26.77K, a 8.08% increase year-over-year.
- TENAX THERAPEUTICS, INC. amortization of leased asset for the quarter ending 2022-03-31 was $26.26K, a 9.73% decline year-over-year.
- TENAX THERAPEUTICS, INC. amortization of leased asset for the quarter ending 2021-12-31 was $25.75K, a 9.67% decline year-over-year.
- TENAX THERAPEUTICS, INC. amortization of leased asset for the quarter ending 2021-09-30 was $25.26K, a 9.61% decline year-over-year.
- TENAX THERAPEUTICS, INC. amortization of leased asset for fiscal 2021 was $104.87K, a 5.25% decline from fiscal 2020.
- TENAX THERAPEUTICS, INC. amortization of leased asset for fiscal 2020 was $110.67K, a 8.22% increase from fiscal 2019.
- TENAX THERAPEUTICS, INC. amortization of leased asset for fiscal 2019 was $102.26K.
- TENAX THERAPEUTICS, INC. amortization of leased asset for fiscal 2018 was $0.00.
| Period end | Amortization of Leased Asset 3 month | Amortization of Leased Asset 6 month | Amortization of Leased Asset 9 month | Amortization of Leased Asset 12 month |
|---|---|---|---|---|
| 2022-06-30 | $26.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $53.03K 10-Q · filed 2022-08-11 | $78.78K derived: sum of 3 quarters · filed 2022-08-11 | $104.04K derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $26.26K 10-Q · filed 2022-05-16 | $52.01K derived: sum of 2 quarters · filed 2022-05-16 | $77.26K derived: sum of 3 quarters · filed 2022-05-16 | $102.03K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-12-31 | $25.75K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $51.01K derived: sum of 2 quarters · filed 2022-03-29 | $75.78K derived: sum of 3 quarters · filed 2022-08-11 | $104.87K 10-K · filed 2022-03-29 |
| 2021-09-30 | $25.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $50.03K derived: sum of 2 quarters · filed 2022-08-11 | $79.11K 10-Q · filed 2021-11-15 | $107.62K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $24.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $53.86K 10-Q · filed 2022-08-11 | $82.37K derived: sum of 3 quarters · filed 2022-08-11 | $110.31K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $29.09K 10-Q · filed 2022-05-16 | $57.60K derived: sum of 2 quarters · filed 2022-05-16 | $85.54K derived: sum of 3 quarters · filed 2022-05-16 | $112.92K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $28.51K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $56.45K derived: sum of 2 quarters · filed 2022-03-29 | $83.83K derived: sum of 3 quarters · filed 2022-03-29 | $110.67K 10-K · filed 2022-03-29 |
| 2020-09-30 | $27.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $55.32K derived: sum of 2 quarters · filed 2021-11-15 | $82.16K 10-Q · filed 2021-11-15 | $108.48K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $27.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $54.22K 10-Q · filed 2021-08-16 | $80.54K derived: sum of 3 quarters · filed 2021-08-16 | $106.35K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $26.84K 10-Q · filed 2021-05-17 | $53.16K derived: sum of 2 quarters · filed 2021-05-17 | $78.97K derived: sum of 3 quarters · filed 2021-05-17 | $104.28K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $26.32K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-16 | $52.13K derived: sum of 2 quarters · filed 2021-04-16 | $77.44K derived: sum of 3 quarters · filed 2021-04-16 | $102.26K 10-K/A · filed 2021-04-16 |
| 2019-09-30 | $25.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $51.12K derived: sum of 2 quarters · filed 2020-11-16 | $75.94K 10-Q · filed 2020-11-16 | $75.94K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $25.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $50.13K 10-Q · filed 2020-08-14 | $50.13K derived: sum of 3 quarters · filed 2020-08-14 | $50.13K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $24.82K 10-Q · filed 2020-05-15 | $24.82K derived: sum of 2 quarters · filed 2020-05-15 | $24.82K derived: sum of 3 quarters · filed 2020-05-15 | $24.82K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $0.00 derived: sum of 2 quarters · filed 2020-03-30 | $0.00 derived: sum of 3 quarters · filed 2020-03-30 | $0.00 10-K · filed 2020-03-30 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |